KALA BIO, Inc. (KALA) Q4 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the Call of Pharmaceuticals conference call to review its fourth quarter and full year 2021 financial results. At this time, all participants are in listen-only mode. Following management's prepared remarks, a Q&A session will be held. As a reminder, this call is being recorded. I would like to turn the call over to Jill Steyer, Executive Director, Investor Relations and Corporate Communications for Call of Pharmaceuticals. Please proceed. Thank you, Operator, and thank you all for participating in today's call. Joining me from the company are Mark Iwicki, Chairman and Chief Executive Officer, Todd Bazemore, President and Chief Operating Officer, Tim Brazel, Head of R&D and Chief Medical Officer, Mary Remeth, Chief Financial Officer, and Darius Karabi, our Chief Business Officer, will also be joining us for the Q&A portion of today's call. Today's call is being webcast live. The webcast link can be found in the investor section of our website at www.callrx.com. During this call, we will be referring to non-GAAP financial measures which are not prepared in accordance with generally accepted accounting principles. A reconciliation of the non-GAAP financial measures to the most direct comparable GAAP measures is available in our press release issued today. which can also be found on our website. On this call, we will make certain comments about COLA's future expectations, plans, and prospects that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements will include statements regarding our commercialization of ISUBIS and INVELTUS, statements regarding the development programs and market potential for KPI 012 and updates on our preclinical programs and the sufficiency of our c...